3.9 Article

Mechanism of attenuation of leptin signaling under chronic ligand stimulation

期刊

BMC BIOCHEMISTRY
卷 11, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2091-11-2

关键词

-

资金

  1. Deutsche Forschungsgemeinschaft [SFB 542]

向作者/读者索取更多资源

Background: Leptin is an adipocyte-derived hormone that acts via its hypothalamic receptor (LEPRb) to regulate energy balance. A downstream effect essential for the weight-regulatory action of leptin is the phosphorylation and activation of the latent transcription factor STAT3 by LEPRb-associated Janus kinases (JAKs). Obesity is typically associated with chronically elevated leptin levels and a decreased ability of LEPRb to activate intracellular signal transduction pathways (leptin resistance). Here we have studied the roles of the intracellular tyrosine residues in the negative feedback regulation of LEPRb-signaling under chronic leptin stimulation. Results: Mutational analysis showed that the presence of either Tyr985 and Tyr1077 in the intracellular domain of LEPRb was sufficient for the attenuation of STAT3 phosphorylation, whereas mutation of both tyrosines rendered LEPRb resistant to feedback regulation. Overexpression and RNA interference-mediated downregulation of suppressor of cytokine signaling 3 (SOCS3) revealed that both Tyr985 and Tyr1077 were capable of supporting the negative modulatory effect of SOCS3 in reporter gene assays. In contrast, the inhibitory effect of SOCS1 was enhanced by the presence of Tyr985 but not Tyr1077. Finally, the reduction of the STAT-phosphorylating activity of the LEPRb complex after 2 h of leptin stimulation was not accompanied by the dephosphorylation or degradation of LEPRb or the receptor-associated JAK molecule, but depended on Tyr985 and/or Tyr1077. Conclusions: Both Tyr985 and Tyr1077 contribute to the negative regulation of LEPRb signaling. The inhibitory effects of SOCS1 and SOCS3 differ in the dependence on the tyrosine residues in the intracellular domain of LEPRb.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Cell Biology

Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (HIPK)

Jan van der Laden, Ulf Soppa, Walter Becker

CELL COMMUNICATION AND SIGNALING (2015)

Editorial Material Biochemistry & Molecular Biology

DYRK protein kinases

Ulf Soppa, Walter Becker

CURRENT BIOLOGY (2015)

Article Chemistry, Medicinal

10-lodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A

Hannes Falke, Apirat Chaikuad, Anja Becker, Nadege Loaec, Olivier Lozach, Samira Abu Jhaisha, Walter Becker, Peter G. Jones, Lutz Preu, Knut Baumann, Stefan Knapp, Laurent Meijer, Conrad Kunick

JOURNAL OF MEDICINAL CHEMISTRY (2015)

Article Chemistry, Medicinal

Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives

Sarah S. Darwish, Mohammad Abdel-Halim, Mohamed Salah, Ashraf H. Abadi, Walter Becker, Matthias Engel

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)

Article Biochemistry & Molecular Biology

Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design

Rosanna Meine, Walter Becker, Hannes Falke, Lutz Preu, Nadege Loaec, Laurent Meijer, Conrad Kunick

MOLECULES (2018)

Article Biology

Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism

Esti Wahyu Widowati, Sabrina Ernst, Ralf Hausmann, Gerhard Mueller-Newen, Walter Becker

BIOLOGY OPEN (2018)

Article Chemistry, Medicinal

Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification

Sarah S. Darwish, Mohammad Abdel-Halim, Ahmed K. ElHady, Mohamed Salah, Ashraf H. Abadi, Walter Becker, Matthias Engel

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)

Article Multidisciplinary Sciences

The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2

Florian Glenewinkel, Michael J. Cohen, Cason R. King, Sophie Kaspar, Simone Bamberg-Lemper, Joe S. Mymryk, Walter Becker

SCIENTIFIC REPORTS (2016)

Article Multidisciplinary Sciences

DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain

Samira Abu Jhaisha, Esti W. Widowati, Isao Kii, Rie Sonamoto, Stefan Knapp, Chrisovalantis Papadopoulos, Walter Becker

SCIENTIFIC REPORTS (2017)

Article Biochemistry & Molecular Biology

How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine

Anne Wurzlbauer, Katharina Rueben, Ece Guerdal, Apirat Chaikuad, Stefan Knapp, Wolfgang Sippl, Walter Becker, Franz Bracher

MOLECULES (2020)

Article Oncology

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN

Stefan Tillmann, Kathrin Olschok, Sarah K. Schroeder, Marlena Buetow, Julian Baumeister, Milena Kalmer, Vera Preussger, Barbora Weinbergerova, Kim Kricheldorf, Jiri Mayer, Blanka Kubesova, Zdenek Racil, Martina Wessiepe, Joerg Eschweiler, Susanne Isfort, Tim H. Brummendorf, Walter Becker, Mirle Schemionek, Ralf Weiskirchen, Steffen Koschmieder, Nicolas Chatain

Summary: Lipocalin 2 (LCN2), a proinflammatory mediator, is involved in the pathogenesis of myeloproliferative neoplasms (MPN). The overexpression of LCN2 in MPN is strongly correlated with driver oncogenes BCR-ABL and JAK2V617F, as well as with endoplasmic reticulum (ER) stress and the unfolded protein response (UPR). Targeting the IRE1-JNK-NF-kappa B-C/EBP axis may represent a promising novel therapeutic approach in MPN.

CANCERS (2021)

Article Biochemistry & Molecular Biology

Discovery of Hydroxybenzothiazole Urea Compounds as Multitargeted Agents Suppressing Major Cytotoxic Mechanisms in Neurodegenerative Diseases

Youssef Aboushady, Moustafa Gabr, Ahmed K. ElHady, Mohamed Salah, Ashraf H. Abadi, Gerrit Wilms, Walter Becker, Mohammad Abdel-Halim, Matthias Engel

Summary: Multiple factors are involved in the progression of Alzheimer's and Parkinson's diseases. The study optimized Dyrk1A inhibitors, leading to the development of a novel compound with triple inhibitory effects against Dyrk1A kinase activity and aggregation of tau and alpha-syn oligomers. Efficacy was demonstrated in cellular models of neurotoxic mechanisms relevant to neurodegenerative diseases.

ACS CHEMICAL NEUROSCIENCE (2021)

Article Chemistry, Medicinal

Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects

Yasmeen T. AlNajjar, Moustafa Gabr, Ahmed K. ElHady, Mohamed Salah, Gerrit Wilms, Ashraf H. Abadi, Walter Becker, Mohammad Abdel-Halim, Matthias Engel

Summary: The study found that dual inhibitors with higher selectivity for Dyrk1A and inhibition of alpha-synuclein aggregation present a potential novel therapeutic strategy for Parkinson's disease. Compound b27, displaying the highest inhibitory potency and selectivity, could be a promising drug candidate for PD treatment.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)

Article Multidisciplinary Sciences

Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B

Marco Papenfuss, Svenja Luetzow, Gerrit Wilms, Aaron Babendreyer, Maren Flasshoff, Conrad Kunick, Walter Becker

Summary: This study reveals the differences between two closely related protein kinases during initial folding and as mature kinases. DYRK1B has a weaker capacity for autonomous maturation compared to DYRK1A in a bacterial expression system. This difference is mainly attributed to the divergent sequences of the C-terminal lobes of the catalytic domain. Additionally, the mature kinase domain of DYRK1B shows lower thermal stability than that of DYRK1A under heat challenge.

SCIENTIFIC REPORTS (2022)

暂无数据